Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Pharmaxis targeting scar-free recovery from burns with world-first trials
    • News

    Pharmaxis targeting scar-free recovery from burns with world-first trials

    One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS).  The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play

    Read More
    Public
  • Infrastructure development surge drives record month for Acrow scaffolding services
    • News

    Infrastructure development surge drives record month for Acrow scaffolding services

    Pushes in infrastructure development across Australia’s major cities is driving demand for scaffolding and support with product hiring specialists Acrow (ASX: ACF) reporting a record month of hire contract wins in March, totaling $5.9 million for the month. The record month tops the previous held in November 2020 by 18% and continues a purple patch

    Read More
    Public
  • Harris Technology to bring top gaming brands to Australia amid industry growth
    • News

    Harris Technology to bring top gaming brands to Australia amid industry growth

    While locked down through the pandemic, gaming emerged as one of the most popular means of entertainment. As first-time gamers are now evolving and driving industry growth, Harris Technology (ASX: HT8) has signed reseller deals to bring two of the world’s most popular gaming product brands into its portfolio. Although pandemic lockdowns have now eased,

    Read More
    Public
  • With their mind blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?
    • Opinion

    With their mind blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?

    The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medical treatment within a legitimate listed sector? As a likely precursor to more local action in the (mind) expanding field, cannabis play

    Read More
    Public
  • Workplace digitisation a boon for Cirrus with $6m in new IT contract wins
    • News

    Workplace digitisation a boon for Cirrus with $6m in new IT contract wins

    In a week where Australia has been rocked by cybersecurity attacks, effective management of IT services has become more critical to business management where IT and networking company Cirrus Networks (ASX: CNW) has landed three big contracts. The largest of the contracts is a 3-year extension with the Peter MacCallum Cancer Centre which will increase

    Read More
    Public
  • The market loves a spin-off
    • Opinion

    The market loves a spin-off

    Recently Iluka Resources spun-off their Deterra Royalties business. Deterra earns a royalty on iron ore mining in Mining Area C, located in the Pilbara of Western Australia, as well as some other royalties. To the surprise of few, Iluka Resources and Deterra Royalties now have a combined value far higher than when the two businesses

    Read More
    Public
  • «
  • ‹
  • 517
  • 518
  • 519
  • 520
  • 521
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.